Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dry Eye Syndrome Clear all
Terminated Not applicable Interventional Results available

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface

NCT02199964
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 20, 2026, 5:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Salivary Proteins in Disease and Health

NCT00100204
View directory record Official record
Conditions
Diabetes Mellitus, Sarcoidosis, Dental Caries, Sjorgren's Syndrome, Cystinosis, Head and Neck Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 5:31 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals

NCT05763940
View directory record Official record
Conditions
Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
Interventions
OmegaBoost, Nature Made (soft gel), Nature Made (gummy)
Dietary Supplement
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

NCT04147650
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

NCT02040623
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution
Drug · Other
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Plantation, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops

NCT00001731
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Cyclosporin A
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Green Tea Lozenges for the Management of Dry Mouth

NCT01647737
View directory record Official record
Conditions
Xerostomia, Sjogren Syndrome, Dry Mouth
Interventions
MighTeaFlow, Xylitol
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 20, 2026, 5:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Staining in a Healthy, Non-Dry Eye Population

NCT00643942
View directory record Official record
Conditions
Normal Healthy Eyes
Interventions
No intervention required
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treating Lid Wiper Epitheliopathy

NCT06671041
View directory record Official record
Conditions
Dry Eye, Visual Acuity
Interventions
Preservative Free eye drop
Drug
Lead sponsor
Southern College of Optometry
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
4
States / cities
Orlando, Florida • Medina, Minnesota • Warwick, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 20, 2026, 5:31 AM EDT
Withdrawn Phase 4 Interventional

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

NCT02028312
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Loteprednol etabonate, Artificial Tears, Restasis
Drug
Lead sponsor
Edward Holland, MD
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Cequa Treatment on Accuracy of Pre-operative Biometry & Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery

NCT04342988
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cequa
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Laguna Hills, California • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease

NCT00758784
View directory record Official record
Conditions
Dry Eye Disease
Interventions
bromfenac ophthalmic solution 0.06%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Total30 For Contact Lens Dropouts

NCT06967298
View directory record Official record
Conditions
Dry Eye, Contact Lens Complication, Contact Lenses
Interventions
T30 Contact lenses
Device
Lead sponsor
Southern College of Optometry
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants

NCT05878067
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
ABBV-444
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2Phase 3 Interventional

Study of TOP1630 for Dry Eye Syndrome

NCT03833388
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TOP1630 0.1% Ophthalmic Solution TID OU, Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
Drug
Lead sponsor
Topivert Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Lewiston, Maine • Andover, Massachusetts • Raynham, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 20, 2026, 5:31 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Usability Study of External Neuromodulation With iTEAR100 Generation 2

NCT05304650
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
iTEAR100
Device
Lead sponsor
Olympic Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Issaquah, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 20, 2026, 5:31 AM EDT
Completed No phase listed Observational

Salivary Biomarkers for Sjögren's Syndrome Detection

NCT01807689
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

NCT03817424
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis
Interventions
VIB7734, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Anniston, Alabama • Birmingham, Alabama • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 20, 2026, 5:31 AM EDT
Completed No phase listed Observational

Prospective Health Assessment of Cataract Patients' Ocular Surface

NCT01016405
View directory record Official record
Conditions
Dry Eye
Interventions
Not listed
Lead sponsor
Innovative Medical
Industry
Eligibility
55 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Dysfunction Management With ZEST Protocol

NCT03968731
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndromes, Ocular Surface Disease
Interventions
Zocular Eyelid System Treatment
Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 20, 2026, 5:31 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Ocular Complications From Cancer Therapy - Patient Registry and Biobank

NCT06874283
View directory record Official record
Conditions
Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease
Interventions
Eye exam
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK

NCT07155070
View directory record Official record
Conditions
Dry Eye
Interventions
Kera Sol Eye Drops
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

NCT03088605
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TOP1630 Ophthalmic Solution, Placebo to TOP1630 Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 20, 2026, 5:31 AM EDT